25.08.2023
BBS-Bioactive Bone Substitutes Plc: Half-Year Financial Report 1 Jan - 30 Jun 2023 (unaudited)
17.08.2023
Conversion of convertible notes pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and Riverfort Global Opportunities PCC Ltd
07.08.2023
BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Ahti Paananen
07.08.2023
BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Jarmo Halonen
07.08.2023
BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Pekka Jalovaara
14.07.2023
BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd
03.07.2023
BBS-Bioactive Bone Substitutes Plc: BBS-Bioactive Bone Substitutes Plc’s rights issue raised gross proceeds of EUR 1.84 million
07.06.2023
BBS-Bioactive Bone Substitutes Plc: 57% of warrants 2-2022 (TO2) used for the subscription of shares, company raises EUR 162,000 in gross proceeds
05.06.2023
BBS-Bioactive Bone Substitutes Plc: BBS arranges a rights offering of approximately maximum EUR 2.9 million
26.05.2023
BBS-Bioactive Bone Substitutes Plc – Inside information – Positive decision received on the product classification, schedule for the quality system approval to be updated
22.05.2023
BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd
19.05.2023
BBS-Bioactive Bone Substitutes Oyj: The subscription period for the second warrant series starts on 22 May 2023 – the subscription price is EUR 0.65 per share
31.03.2023
BBS-Bioactive Bone Substitutes Plc has renewed a capital facility with RiverFort Global Opportunities PCC
30.03.2023
BBS-Bioactive Bone Substitutes Plc: Decisions of the Annual General Meeting 2023
27.03.2023
BBS-Bioactive Bone Substitutes – Inside information: The final report of the second audit received from the Notified Body, CE marking process may continue and CE marking approval continues to be expected during 2023
09.03.2023
BBS-Bioactive Bone Substitutes Plc: Notice to the BBS-Bioactive Bone Substitutes Plc’s Annual General Meeting
09.03.2023
BBS-Bioactive Bone Substitutes Plc: BBS-Bioactive Bone Substitutes Plc: Annual Report for 2022 has been published
24.02.2023
BBS-Bioactive Bone Substitutes Plc: Financial Statements Bulletin, 1 January – 31 December 2022 (unaudited)
16.02.2023
BBS-Bioactive Bone Substitutes: Approved delisting application regarding the secondary listing on the Nasdaq First North Growth Market Sweden
13.02.2023
BBS-Bioactive Bone Substitutes Plc Applies for The Delisting of Secondary Listing on Nasdaq First North Growth Market Sweden
30.12.2022
BBS-Bioactive Bone Substitutes Plc - Insider information: BBS updates estimate of the CE marking approval schedule of ARTEBONE® Paste
14.12.2022
BBS-Bioactive Bone Substitutes Plc: Financial calendar and Annual General Meeting in 2023
09.12.2022
BBS-Bioactive Bone Substitutes: 69% of the warrants 1-2022 (WA1) used for the subscription of shares, company raises EUR 213 000 in gross proceeds
18.11.2022
BBS-Bioactive Bone Substitutes Oyj: The subscription period for the first warrant series starts on 21 November 2022 – the subscription price is EUR 0.92 per share
18.11.2022
BBS-Bioactive Bone Substitutes – Inside information: The first audit completed by the Notified Body, CE marking process may continue as planned
04.11.2022
BBS-Bioactive Bone Substitutes announces plans to withdraw its dual listing on Nasdaq First North Growth Market Sweden
04.11.2022
BBS-Bioactive Bone Substitutes has resolved on a share issue without consideration to the company itself
07.10.2022
Jari Kortesluoma appointed as CFO and member of the management team of BBS-Bioactive Bone Substitutes Plc
31.08.2022
BBS-Bioactive Bone Substitutes Plc: Managers’ Transactions – Pekka Jalovaara
31.08.2022
BBS-Bioactive Bone Substitutes Plc: Managers’ Transactions – Ahti Paananen
31.08.2022
BBS-Bioactive Bone Substitutes Plc: Change in BBS-Bioactive Bonesubstitutes Plc’s management
25.08.2022
BBS-Bioactive Bone Substitutes Plc: Managers’ Transactions – Oili Halonen
25.08.2022
BBS-Bioactive Bone Substitutes Plc: Managers’ Transactions – Pekka Jalovaara
25.08.2022
BBS-Bioactive Bone Substitutes Plc: Managers’ Transactions – Jarmo Halonen
25.08.2022
BBS-Bioactive Bone Substitutes Plc: Half-Year Financial Report, 1 January – 30 June 2022 (unaudited)
08.08.2022
Changes in the BBS-Bioactive Bone Substitutes Plc’s Management Team
28.06.2022
BBS-Bioactive Bone Substitutes Plc: Trading on BBS’s warrants begins on First North Growth Market Finland
08.06.2022
BBS-Bioactive Bone Substitutes Plc’s rights issue raised gross proceeds of EUR 3.5 million
09.05.2022
BBS publishes EU growth prospectus in connection to its EUR 4.5 million rights issue
06.05.2022
BBS-Bioactive Bone Substitutes Plc: BBS arranges a rights issue of approximately maximum 4.5 MEUR with additional warrants
29.04.2022
BBS-Bioactive Bone Substitutes Plc: Decisions of the Annual General Meeting 2022
05.04.2022
Invitation to the Bbs-Bioactive Bone Substitutes Plc’s Annual General Meeting (AGM)
29.03.2022
BBS-Bioactive Bone Substitutes Plc: ANNUAL REPORT 2021 has been published
17.03.2022
BBS-Bioactive Bone Substitutes Plc: Decisions of the Extraordinary General Meeting 2022
09.03.2022
BBS Bioactive Bone Substitutes Plc has filed the CE-marking application of Artebone® bone void filler to the authorities
24.02.2022
Invitation to the Extraordinary General Meeting of Bbs-Bioactive Bone Substitutes Plc
24.02.2022
BBS-Bioactive Bone Substitutes Plc: Financial Statements Review 1.1.-31.12.2021 (unaudited)
23.02.2022
Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and RiverFort to strengthen the working capital position
11.01.2022
BBS-Bioactive Bone Substitutes Plc: US Patent for the Manufacture of ARTEBONE® product
10.12.2021
BBS-Bioactive Bone Substitutes Plc: Financial calendar and Annual General Meeting in 2022
19.11.2021
BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc ja Riverfort Global Opportunities PCC Ltd
17.11.2021
BBS-Bioactive Bone Substitutes Plc: Claims of the patent application for the manufacturing of the ARTEBONE® product have been approved in the USA
30.09.2021
BBS-Bioactive Bone Substitutes Plc has agreed on a capital facility to strengthen the company's working capital – further enables the CE marking application
07.09.2021
BBS-Bioactive Bone Substitutes Plc: Animal test results completed contributing on their part to submitting the CE marking application
25.08.2021
BBS-Bioactive Bone Substitutes Plc: CORRECTION: Half-Year Report January 1st –June 30th 2021 (Unaudited)
25.08.2021
BBS-Bioactive Bone Substitutes Plc: Half-Year Report January 1st –June 30th 2021 (Unaudited)
29.04.2021
BBS-Bioactive Bone Substitutes Plc - CORRECTION: Decisions of the Annual General Meeting 2021
28.04.2021
BBS-Bioactive Bone Substitutes Plc: Decisions of the Annual General Meeting 2021
26.04.2021
BBS-Bioactive Bone Substitutes Plc: Submission of CE marking application for ARTEBONE® products moves to August
08.04.2021
BBS-Bioactive Bone Substitutes Plc: CORRECTION TO THE INVITATION TO THE ANNUAL GENERAL MEETING
07.04.2021
BBS-Bioactive Bone Substitutes Plc: INVITATION TO THE BBS-BIOACTIVE BONE SUBSTITUTES PLC’S ANNUAL GENERAL MEETING (AGM)
31.03.2021
BBS-Bioactive Bone Substitutes Plc: ANNUAL REPORT 2020 has been published
24.02.2021
BBS-Bioactive Bone Substitutes Plc: Financial Statements Review 1.1.-31.12.2020 (unaudited)
01.02.2021
BBS-Bioactive Bone Substitutes Plc: CFO will change on 1 February, 2021
11.01.2021
BBS-Bioactive Bone Substitutes Plc: New Schedule Estimate for the CE Marking of Company’s ARTEBONE® Product
23.12.2020
BBS-Bioactive Bone Substitutes Plc: Correction to the release of BBS-Bioactive Bone Substitutes Plc published on 21.12.2020 at 16:30 CET
21.12.2020
BBS-Bioactive Bone Substitutes Plc: BBS-Bioactive Bone Substitutes' financial calendar and Annual General Meeting in 2021
08.12.2020
BBS-Bioactive Bone Substitutes Plc: The information published in the Company Announcement by BBS-Bioactive Bone Substitutes Plc. on 9 November 2020 at 8:45 has proved to be incorrect
09.11.2020
BBS-Bioactive Bone Substitutes Plc: The whole patent regarding the product ARTEBONE® has been accepted in the USA
07.08.2020
BBS-Bioactive Bone Substitutes Plc: The CE marking application of the Company’s ARTEBONEⓇ Paste product is in progress
26.06.2020
BBS-Bioactive Bone Substitutes Plc: Directed share issue to shareholder
25.06.2020
BBS-Bioactive Bone Substitutes Plc: Managers' Transactions
24.06.2020
BBS-Bioactive Bone Substitutes Plc: Final results of the successful rights issue - oversubscribed by 49 percent
12.06.2020
BBS-Bioactive Bone Substitutes Plc: Today is the last day of trading in subscription rights
29.05.2020
BBS-Bioactive Bone Substitutes Plc: The Prospectus of Rights Issue has been published on the Company’s website today
26.05.2020
BBS-Bioactive Bone Substitutes Plc: BBS-Bioactive Bone Substitutes Plc postpones the Annual General Meeting to a later date
26.05.2020
BBS-Bioactive Bone Substitutes Plc: The Board of Directors of BBS-Bioactive Bone Substitutes Plc. decided on a subscription rights issue and publishes the prospectus and issue terms
20.05.2020
BBS-Bioactive Bone Substitutes Plc: BBS-Bioactive Bone Substitutes Plc. plans to arrange a rights issue of approximately 5.5 MEUR
09.04.2020
BBS-Bioactive Bone Substitutes Plc: Financial Statements for 2019 have been published
07.04.2020
BBS-Bioactive Bone Substitutes Plc: The patent regarding the product ARTEBONE® has been granted in the USA
07.04.2020
BBS-Bioactive Bone Substitutes Plc: BBS-Bioactive Bone Substitutes Plc postpones the Annual General Meeting to a later date
27.03.2020
BBS-Bioactive Bone Substitutes Plc: BBS-Bioactive Bone Substitutes Plc has received a working capital loan to secure its financing
20.03.2020
BBS-Bioactive Bone Substitutes Plc: Financial Statements Review 1.1.-31.12.2019 (unaudited)
19.02.2020
BBS-Bioactive Bone Substitutes Plc: We are pleased to announce that the clinical result of ARTEBONE® is positive yielding an outcome similar to patient’s own bone graft
30.12.2019
Liquidation preference ends in Sweden
22.10.2019
BBS-Bioactive Bone Substitutes Plc: The patent application regarding a bone protein preparation has been accepted in Canada
14.10.2019
BBS-Bioactive Bone Substitutes Plc: A new CEO has been selected for BBS
09.07.2019
Correction: BBS share issue completed 215 new shareholders in Sweden
17.06.2019
BBS announces a share issue of approximately 12.7-16.8 MSEK to expand the owner base in Sweden
13.05.2019
Correction: Resolutions of the Annual General Meeting 2019
22.03.2019
Correction to Financial Statement Bulletin of BBS-Bioactive Bone Substitutes Plc, published 22th March 2019 at 9:00 CET
15.03.2019
BBS-Bioactive Bone Substitutes Plc: Correction to the invitation to annual general meeting of BBS-Bioactive Bone Substitutes Plc published on 15.03.2019 at 12:00 CET